NCT01208090 is a Phase 2 clinical trial of ACT-128800 in Psoriasis, sponsored by Actelion.

Who is sponsoring NCT01208090?

NCT01208090 is sponsored by Actelion.

What drugs are being tested in NCT01208090?

Interventions in NCT01208090: ACT-128800, Placebo.

Is NCT01208090 still recruiting?

NCT01208090 is currently completed. Last updated 30 March 2025.

Last reviewed 2025-03-30 · How we verify

NCT01208090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed Phase 2 Last updated 30 March 2025

What this trial tests

Phase 2 trial testing ACT-128800 in Psoriasis in 326 participants. Completed in 30 November 2012.

Timeline

31 October 2010

Primary endpoint
31 October 2012

30 November 2012

Quick facts

Lead sponsor	Actelion
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	326
Start date	31 October 2010
Primary completion	31 October 2012
Estimated completion	30 November 2012
Sites	67 locations across Denmark, France, Italy, Russia, Slovakia, Ukraine, Belgium, Austria

Drugs / interventions tested

ACT-128800 — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Actelion — full company profile →

Who can join

Adults 18 to 60, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Sphingosine 1-phosphate: Lipid signaling in pathology and therapy.
Cartier A, Hla T. · · 2019 · cited 477× · PMID 31624181 · DOI 10.1126/science.aar5551
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.
Kunkel GT, Maceyka M, Milstien S, Spiegel S. · · 2013 · cited 377× · PMID 23954895 · DOI 10.1038/nrd4099
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.
Vaclavkova A, Chimenti S, Arenberger P, Holló P, et al · · 2014 · cited 119× · PMID 25127208 · DOI 10.1016/s0140-6736(14)60803-5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Do G, et al · · 2017 · cited 106× · PMID 29271481 · DOI 10.1002/14651858.cd011535.pub2
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.
Park SJ, Im DS. · · 2017 · cited 103× · PMID 28035084 · DOI 10.4062/biomolther.2016.160
Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.
D'Ambrosio D, Freedman MS, Prinz J. · · 2016 · cited 74× · PMID 26770667 · DOI 10.1177/2040622315617354
The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, et al · · 2020 · cited 53× · PMID 32580348 · DOI 10.3390/cells9061515
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics.
Ben Abdallah H, Johansen C, Johansen C, Iversen L. · · 2021 · cited 48× · PMID 34235053 · DOI 10.2147/ptt.s294173

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Actelion trials

Trials by the same sponsor.

NCT05731492 — A Study of Macitentan in Children Below 2 Years of Age · Phase 1 · withdrawn
NCT05433675 — A Study of Two Macitentan Formulations in Healthy Adult Participants · Phase 1 · completed
NCT05427162 — A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist · Phase 1 · completed
NCT05392530 — A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Particip · Phase 1 · completed
NCT05179876 — A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no O · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01208090 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Actelion
Last refreshed: 30 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01208090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing